Summary |
|
|||||||||||||
Transgene origin |
|
|||||||||||||
Transgene description |
|
|||||||||||||
Phenotypes |
View phenotypes and curated references for all genotypes (concatenated display).
|
|||||||||||||
Disease models |
|
|||||||||||||
Find Mice (IMSR) |
|
|||||||||||||
Notes |
Five transgenic lines were generated on an FVB background. This line expressed the highest SOD2 activity.
Transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. There is an approximately 10 fold increase in SOD2 activity in transgenic islets when compared to wild-type controls. There is no statistical difference in insulin and DNA content, insulin staining and islet morphology or diabetes development following cyclophosphamide treatment between mutant and wild-type NOD mice. Transgenic mice are resistant to diabetes when treated with streptozotocin. Islet beta cells from transgenics generate less ROS when treated with peroxynitrite or superoxide. Untreated mutants do not display accelerated spontaneous diabetes. |
|||||||||||||
References |
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 12/10/2024 MGI 6.24 |
|
|